Muximed (Ambroxol Hydrochloride)

Ambroxol acts on the bronchial epithelium to stimulate serous mucus secretion and to reduce the viscosity of existing secretions. This enhances mucociliary clearance, allowing patients to expectorate mucus more easily and improving airway patency.

The appropriate dose of Muximed is determined by the prescribing healthcare professional based on the patient’s age, condition severity and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for ambroxol in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using Muximed.

To order Muximed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Muximed’s active ingredient, ambroxol, is a well‑studied mucolytic that both stimulates thin mucus production and reduces viscosity, offering a dual mechanism. Compared with agents such as acetylcysteine, ambroxol often has a more favorable taste profile and fewer gastrointestinal side effects, though individual response may vary.

Muximed should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Muximed is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless directed by a healthcare professional. Administration timing (e.g., with meals) follows the prescriber’s guidance.

Serious adverse reactions, although rare, include allergic responses such as urticaria, angioedema, severe skin conditions like Stevens‑Johnson syndrome, hepatic dysfunction, eosinophilia, neutropenia and anaphylaxis. Any of these symptoms require immediate medical attention.

Muximed is contraindicated in individuals with known hypersensitivity to ambroxol or any excipients in the formulation. Patients with severe renal impairment should use it only under medical supervision, and it should be avoided in those with a history of severe allergic reactions to mucolytic agents.